He B, Zhang W, Liu L N, Wang H, Zou Y W, Jiang Y X, Yu W J, Shi H L, Liu Y, Li Y J
Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao 266003, China.
Department of Pathology, 971 Hospital of PLA Navy, Qingdao 266071, China.
Zhonghua Bing Li Xue Za Zhi. 2019 Nov 8;48(11):846-850. doi: 10.3760/cma.j.issn.0529-5807.2019.11.003.
To investigate the clinicopathological characteristics and prognosis of renal cell carcinoma (RCC) in patients with end-stage renal disease (ESRD). The clinicopathological data of patients of renal cell carcinoma arising in end-stage renal disease were collected from the Affiliated Hospital of Qingdao University (ten cases) and 971 Hospital of PLA Navy (five cases) from January 2009 to August 2018. Among 15 patients, 14 were male and 1 was female, and the age ranged from 38 to 78 years (mean 51 years, median 49 years). All patients had history of chronic renal failure (7-192 months), including 9 patients treated with hemodialysis for 6 to 132 months. In 12 cases the tumor border was distinct and the tumor size ranged from 1.8 to 11.0 cm. Two cases were multifocal and one case showed extensive renal hemorrhage with an inconspicuous tumor mass. Microscopically, 9 cases were clear cell reanl cell carcinoma including one with sarcomatoid differentiation, 4 were acquired cystic kidney disease-associated(ACKD-RCC) and two were papillary renal cell carcinoma. All patients had a follow-up of 3 to 120 months. Four patients died during a follow-up of 6 to 60 months (mean 30 months) as a result of extensive distant metastases (two cases) and renal failure (two cases), while other eleven patients were alive without tumor recurrence or metastasis (median 40.8 months of follow-up ranging from 3 to 120 months). ESRD-RCC is more often seen in younger male patients. The time intervals from the onset of chronic renal failure to the diagnosis of renal cell carcinoma differ and tumors are frequently incidental findings. The histological types can be sporadic renal cell carcinoma or unique ACKD-RCC. Tumors are often hemorrhagic and necrotic. Routine physical examination and early detection could benefit ESRD-RCC patients. ESRD-RCC may have a favorable prognosis despite of a large tumor size or the presence of sarcomatoid differentiation.
探讨终末期肾病(ESRD)患者肾细胞癌(RCC)的临床病理特征及预后。收集2009年1月至2018年8月青岛大学附属医院(10例)和解放军海军第九七一医院(5例)终末期肾病患者肾细胞癌的临床病理资料。15例患者中,男性14例,女性1例,年龄38~78岁(平均51岁,中位数49岁)。所有患者均有慢性肾衰竭病史(7~192个月),其中9例接受血液透析治疗6~132个月。12例肿瘤边界清晰,肿瘤大小为1.8~11.0 cm。2例为多灶性,1例表现为广泛肾出血,肿瘤肿块不明显。显微镜下,9例为透明细胞肾细胞癌,其中1例伴有肉瘤样分化,4例为获得性囊性肾病相关性肾细胞癌(ACKD-RCC),2例为乳头状肾细胞癌。所有患者随访3~120个月。4例患者在随访6~60个月(平均30个月)期间死亡,原因是广泛远处转移(2例)和肾衰竭(2例),而其他11例患者存活,无肿瘤复发或转移(随访中位数40.8个月,范围3~120个月)。ESRD-RCC多见于年轻男性患者。从慢性肾衰竭发病到肾细胞癌诊断的时间间隔不同,肿瘤常为偶然发现。组织学类型可为散发性肾细胞癌或独特的ACKD-RCC。肿瘤常伴有出血和坏死。常规体检及早期发现对ESRD-RCC患者有益。尽管肿瘤体积大或存在肉瘤样分化,ESRD-RCC仍可能有较好的预后。